Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02054130 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma

A Phase 2 study of Asthma, sponsored by MedImmune.

Completed
Registry status
Phase 2
Development phase
584
Enrollment target
20
Study locations

NCT02054130: Completed Phase 2 study of Asthma, sponsored by MedImmune.

NCT02054130 is a Phase 2 study of Asthma that has completed, run by MedImmune. The registered enrollment target is 584 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02054130, a Phase 2 study of Asthma, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 2
Development phase
584 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.

Conditions Studied

Asthma

Interventions

  • DRUG Placebo
  • DRUG MEDI9929 70 mg
  • DRUG MEDI9929 210 mg
  • DRUG MEDI9929 280 mg

Study Locations (20)

California

  • Research Site - Los Angeles
  • Research Site - Los Angeles

Florida

  • Research Site - Miami
  • Research Site - Oviedo

New York

  • Research Site - New York
  • Research Site - New York

North Carolina

  • Research Site - Charlotte
  • Research Site - Charlotte

South Carolina

  • Research Site - Rock Hill
  • Research Site - Spartanburg

Other

  • Research Site - Plovdiv
  • Research Site - Sofia

Georgia

  • Research Site - Savannah

Illinois

  • Research Site - Peoria

Trial Details

FieldValue
Enrollment Target 584 participants
Start Date 2013-12-13
Est. Completion 2017-03-01
Phase Phase 2

Sponsor

MedImmune

210 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02054130

The ClinicalTrials.gov registry entry for NCT02054130 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 584 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (63% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT02054130 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT02054130 about?

NCT02054130 is a clinical study titled "Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma". The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.

What is the current status of trial NCT02054130?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 584 participants. The study started on 2013-12-13. Estimated completion is 2017-03-01.

What conditions does trial NCT02054130 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT02054130?

The interventions under investigation include: Placebo (DRUG), MEDI9929 70 mg (DRUG), MEDI9929 210 mg (DRUG), MEDI9929 280 mg (DRUG).

Who is sponsoring clinical trial NCT02054130?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02054130 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.